All In Biotech

Drug Trial Radar · NCT04026997

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Dose Response of Oral CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

72

Actual

Start

Sep 11, 2019

Primary completion

Dec 17, 2020

Study completion Dec 17, 2020

Sponsor

Lead sponsor
CinDome Pharma, Inc.Industry
Sponsor type
Industry
First posted
Jul 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.

Conditions

  • Gastroparesis

Interventions

  • CIN-102 Dose 1Drug

    CIN-102 Dose 1

  • CIN-102 Dose 2Drug

    CIN-102 Dose 2

  • CIN-102 Dose 3Drug

    CIN-102 Dose 3

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14
  2. The Percent Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site 101

    Chula Vista, California

  • Research Site 114

    Jacksonville, Florida

  • Research Site 117

    Miami, Florida

  • Research Site 118

    Miami, Florida

  • Research Site 111

    Atlanta, Georgia

  • Research Site 110

    Kansas City, Kansas

  • Research Site 103

    Louisville, Kentucky

  • Research Site 112

    Marrero, Louisiana

  • Research Site 104

    Monroe, Louisiana

  • Research Site 102

    Boston, Massachusetts

  • Research Site 121

    Omaha, Nebraska

  • Research Site 113

    Las Vegas, Nevada

  • Research Site 109

    Great Neck, New York

  • Research Site 120

    Winston-Salem, North Carolina

  • Research Site 105

    Tulsa, Oklahoma

  • Research Site 106

    Philadelphia, Pennsylvania

  • Research Site 119

    Summerville, South Carolina

  • Research Site 115

    Rapid City, South Dakota

  • Research Site 107

    Jackson, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.